close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
53 54 Next >
Hepatocellular Carcinoma Market and Epidemiology 2032: Treatment Therapies, FDA Approvals, Companies and Market Forecasting by DelveInsight | AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Takeda
Via AB Newswire
Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma
Via AB Newswire
Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia
Via AB Newswire
Cystic Fibrosis Pipeline, Clinical Trials, and Key Companies|Companies – Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma
Via AB Newswire
News headline image
Health Care Company Novartis Announces Merger With Chinook Therapeutics ↗
 
Via Benzinga
News headline image
Is Novartis a Good Stock to Buy Right Now? ↗
The multinational pharma giant excels as an income play. 
Via The Motley Fool
News headline image
Looking At Novartis's Recent Unusual Options Activity ↗
 
Via Benzinga
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
Via AB Newswire
KRAS Inhibitors Market to Witness Growth by 2032, Estimates DelveInsight | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio
Via AB Newswire
News headline image
Novartis Stock Screams Value After Chinook Therapeutics Buyout
Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock. 
Via MarketBeat
IgA Nephropathy Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alnylam, RemeGen, Novartis, Visterra/ Otsuka, Vera Therapeutics, Omeros Corp.
Via AB Newswire
News headline image
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook ↗
Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock. 
Via InvestorPlace
Bone Neoplasms Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Amgen, Novartis, Roche, Merck, Luye Pharma, Bayer, Pfizer.
Via AB Newswire
Opioid-Induced Constipation Market expected to rise | Companies – Cosmo Pharmaceuticals, Shionogi & Co., Merck & Co, Novartis AG, AstraZeneca plc, Bausch Health Companies, expected to boost the market
Via AB Newswire
Food Allergy Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Alladapt, Regeneron, InnoUp Farma, Novartis, Genentech, DBV Technologies
Via AB Newswire
News headline image
Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover ↗
Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company. 
Via Investor's Business Daily
News headline image
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust ↗
Find out more about two big winners Monday morning. 
Via The Motley Fool
News headline image
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
News headline image
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories ↗
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger 
Via Benzinga
News headline image
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today? ↗
Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS). 
Via InvestorPlace
Hidradenitis Suppurativa Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | InflaRx, Novartis, ChemoCentryx, AnaptysBio, AbbVie, UCB Biopharma
Via AB Newswire
Exploring Novel Approaches to Diabetic Retinopathy Pipeline and Clinical Trials (2023) | Companies – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular , Bayer, and Others
Via AB Newswire
Breakthrough Therapies and Potential Targets for Complement 3 Glomerulopathy Pipeline Analysis (2023) | Companies – ChemoCentryx, Novartis Pharma, Omeros Corporation, Apellis Pharma, and others
Via AB Newswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
News headline image
Why Are Chinook Therapeutics Shares Trading Higher Today ↗
Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,  
Via Benzinga
News headline image
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗
 
Via Benzinga
News headline image
Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
News headline image
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations ↗
Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its  
Via Benzinga
News headline image
Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson
Stay up-to-date with Veterinary Healthcare Product Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin 
Via MarketBeat
Topics Death
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today